Latest quarter
Eli Lilly reported Q3 FY2026 revenue of $24.4 billion, above the $22.1 billion consensus and up 38.6% from a year earlier. Adjusted earnings per share were $7.48, above the $5.38 consensus.
Lilly’s filing attributed revenue growth primarily to higher volumes, partly offset by lower realized prices, with Mounjaro and Zepbound driving both trends. The company said combined quarterly sales of the two medicines reached $16.1 billion. The filing said Mounjaro’s growth outside the U.S. was driven by volume, while its inclusion on China’s reimbursement list reduced realized prices.
Gross margin rose to 83.9% from 82.9% a year earlier; Lilly attributed the increase mainly to production costs and product mix, partly offset by lower prices. Operating margin fell to 36.5% from 43.9%. The filing said higher acquired research charges and operating expenses partly offset the effect of higher gross margin on earnings.
Free cash flow was $8.2 billion, compared with $6.7 billion a year earlier. CFO Lucas Montarce said quarterly revenue included approximately $900.0 million from items including milestones and changes in rebate and discount estimates.
| Q3 FY2026 | Q3 FY2025 | Change | |
|---|---|---|---|
| Revenue | $24.4 billion | $17.6 billion | 38.6% |
| Diluted EPS | $7.22 | $6.21 | 16.3% |
| Gross margin | 83.9% | 82.9% | 1.0 percentage point |
| Operating margin | 36.5% | 43.9% | −7.4 percentage points |
| Free cash flow | $8.2 billion | $6.7 billion | 21.8% |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | $7.48 | $5.38 | Beat by 39.0% |
| Revenue | $24.4 billion | $22.1 billion | Beat by 10.4% |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
CEO David Ricks said the Medicare GLP-1 Bridge program had expanded access to obesity medicines for seniors, with more than 500,000 people filling a Lilly prescription through it since launch. Asked about the program, Ilya Yuffa, president of Lilly USA and Global Customer Capabilities, said 80.0% of people receiving treatment through Bridge had not previously been on therapy. He said lower out-of-pocket costs helped patients stay on treatment, adding that “a low out of pocket helps with that friction point.”
CFO Lucas Montarce said U.S. revenue growth was driven by Zepbound and Mounjaro volumes, partly offset by lower prices. He said favorable product mix and production costs supported the gross margin, while lower realized prices provided an offset. Montarce also said spending on research and development and promotion rose as Lilly invested in its pipeline and product launches.
Analysts asked whether incretin growth had been pulled forward. Montarce replied that Lilly was still reaching a small share of potential patients and said, “we are still scratching the surface on the number of patients that we can reach.” Asked about competition and pricing outside the U.S., Lilly International president Patrik Jonsson said the company had maintained its share and continued to grow following generic launches in several markets.
On Foundayo, Jonsson said international launches were in line with expectations and that oral medicines were bringing new patients into the market. Yuffa said U.S. awareness and provider adoption had improved, although he expected adherence to oral medicines to be lower than for weekly injections.
Ricks said Lilly had begun building manufacturing facilities in Texas and Virginia. Looking ahead, Montarce said Lilly expected U.S. incretin volume growth and a full year of Bridge access in 2027, while Yuffa expected commercial access to remain relatively stable.
Guidance
Lilly raised its FY2026 revenue guidance and now expects $91.0 billion to $92.0 billion. It revised its non-GAAP earnings-per-share outlook to $35.00 to $36.00; Montarce said the outlook reflected updated acquired research charges.
For 2027, Montarce said Lilly expects volume growth to more than offset a net realized price headwind. He said the company would provide its 2027 financial guidance on its Q4 call.
| Metric | For | Guide | Previous guide | Change |
|---|---|---|---|---|
| Units | FY2027 | Eli Lilly expects volume growth to more than offset a net realized price headwind in FY2027. | — | — |
| Market share, Mounjaro International | FY2027 | Eli Lilly expects Mounjaro to maintain its market leadership outside the U.S. in FY2027. | — | — |
| Market size, US Incretin Market | FY2027 | Eli Lilly expects sustained volume growth in the U.S. incretin market in FY2027. | — | — |
| EPS, non-GAAP | FY2026 | $35.00–$36.00 | $35.50–$36.50 | Cut |
| Operating margin, non-GAAP | FY2026 | 52.5% | — | New |
| Revenue | FY2026 | $91.0 billion–$92.0 billion | $85.0 billion–$87.0 billion | Raised |
| Tax rate, non-GAAP | FY2026 | 19.0%–20.0% | — | New |
| EPS | FY2026 | $35.50–$37.00 | — | New |
| Operating margin | FY2026 | 47.0%–48.5% | — | New |